Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease

Completed · Phase 4

Conditions studied: End Stage Renal Disease

In brief

The purpose of the study is to determine the response of 13-valent conjugate pneumococcal vaccine in patients 50 years or older with end stage renal disease on dialysis. The study will also try to determine Streptococcus pneumoniae colonization in patients 50 years or older with end stage renal disease on dialysis.

Key facts

Study ID

NCT01974817

Run by

Michigan State University

People needed

25

Starts

2013-05-01

Expected to finish

2014-12-01

Last updated by the study team

2016-11-17

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients ≥ 50years of age with End stage renal disease on dialysis (both hemodialysis and peritoneal dialysis).
• Scheduled to receive pneumococcal vaccine either after 5years of previous vaccination or starting vaccination as part of standard care during the study period

You may not qualify if…

• History of S. pneumoniae infection within the last 5 years
• Vaccinated with an influenza- or diphtheria-containing vaccine within the last 6 months
• History of any severe adverse reaction associated with a vaccine
• Received gamma-globulins within the previous 6 months
• Known or suspected HIV or on immunosuppressive medications.
• Functional or anatomic asplenia
• serious chronic medical condition

Where it is running

• Sparrow Dialysis at Saint Lawrence Campus — Lansing, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.